Inhibrx Biosciences, Inc.(INBX)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Rank #2,506 of 2,961 stocks
Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.
Revenue Growth
Profitability
Balance Sheet
Earnings Quality
Free Cash Flow
Institutional Flow
Revenue Scale
Dilution Risk
Unusual Activity in INBX
Events flagged as statistical outliers against INBX's own multi-year baseline — not fixed dollar thresholds.
- Record insider buy2026-09-08
Largest insider buy on record for INBX: Lappe Mark (Chief Executive Officer) purchased $1,087,001
View source filing → - Insider cluster2026-09-08
3 insiders bought $3,499,597 of INBX in 30 days — 6.0σ above this company's 2-year norm
View source filing →
INBX Stock Analysis & AI Quality Score
Data updated 2026-09-11AI stock analysis and institutional research for Inhibrx Biosciences, Inc. (INBX), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores INBX at 30.0/100 on a 32-signal composite quality model, placing it at rank #2,506 of 2,961 stocks — the bottom half of the AI-ranked universe. INBX scores in the top quartile across revenue growth (95.7), institutional flow (90.4). Areas of concern include free cash flow (0.4) and revenue scale (0.4), which score below median versus the broader universe. Shareholder dilution risk is elevated at 0.8/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), Inhibrx Biosciences, Inc. reports net income of $-36.6M, free cash flow of $-29.9M. Top institutional holders of INBX by reported 13-F value include MORGAN STANLEY, PERCEPTIVE ADVISORS, Sanofi, based on the most recent SEC filings. INBX trades on the Nasdaq exchange and files with the SEC under CIK 2007919. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate INBX daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Inhibrx Biosciences, Inc. directly from SEC EDGAR. Inhibrx Biosciences, Inc.'s 13F Pro composite quality score has ranged between 14 and 45 since 2025, currently 30.0 — a declining long-term trajectory across 52 quarterly and live scoring snapshots.
Revenue
Q2 2026
$0.00
Net Income
Q2 2026
$-36.6M
Free Cash Flow
Q2 2026
$-29.9M
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · ProRevenue
+550.0% YoYNet Income
-108.3% YoYOperating Income
+59.3% YoYEPS (Diluted)
-108.0% YoYTotal Assets
-19.0% YoYTotal Debt
Op. Cash Flow
+33.2% YoYFree Cash Flow
+34.1% YoY| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Revenue | $1.3M +550.0% | $200.0K -88.9% | $1.8M | — |
| Net Income | $-140.1M -108.3% | $1.69B +799.2% | $-241.4M | — |
| Operating Income | $-135.0M +59.3% | $-331.4M -51.2% | $-219.2M | — |
| EPS (Diluted) | $-9.04 -108.0% | $112.62 +649.9% | $-20.48 | — |
| Total Assets | $146.5M -19.0% | $180.8M -41.3% | $307.9M | — |
| Total Debt | $100.6M | $0.00 -100.0% | $207.0M | — |
| Operating Cash Flow | $-129.8M +33.2% | $-194.4M -0.6% | $-193.3M | — |
| Free Cash Flow | $-129.8M +34.1% | $-197.0M +0.5% | $-197.9M | — |
Get alerted when INBX's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for Inhibrx Biosciences, Inc. including:
Top Institutional Holders of INBX
MORGAN STANLEY
$123.9M1,308,051 shPERCEPTIVE ADVISORS LLC
$123.0M1,297,763 shSanofi
$109.7M1,157,926 shVIKING GLOBAL INVESTORS LP
$106.5M1,123,929 shHighTower Advisors, LLC
$82.5M870,551 shBANK OF AMERICA CORP /DE/
$79.7M841,141 shBlackRock, Inc.
$78.3M825,972 shSchonfeld Strategic Advisors LLC
$66.1M697,586 shSTATE STREET CORP
$60.7M640,458 shVANGUARD CAPITAL MANAGEMENT LLC
$46.7M492,477 sh
| Fund | Value | Shares |
|---|---|---|
| MORGAN STANLEY | $123.9M | 1,308,051 |
| PERCEPTIVE ADVISORS LLC | $123.0M | 1,297,763 |
| Sanofi | $109.7M | 1,157,926 |
| VIKING GLOBAL INVESTORS LP | $106.5M | 1,123,929 |
| HighTower Advisors, LLC | $82.5M | 870,551 |
| BANK OF AMERICA CORP /DE/ | $79.7M | 841,141 |
| BlackRock, Inc. | $78.3M | 825,972 |
| Schonfeld Strategic Advisors LLC | $66.1M | 697,586 |
| STATE STREET CORP | $60.7M | 640,458 |
| VANGUARD CAPITAL MANAGEMENT LLC | $46.7M | 492,477 |
Companies Similar to INBX
Ranked by quality-profile closeness and shared hedge-fund ownership — not just sector membership.
ANAPTYSBIO, INC
4D Molecular Therapeutics, Inc.
PROKIDNEY CORP.
RHYTHM PHARMACEUTICALS, INC.
Altimmune, Inc.
Upstream Bio, Inc.
Atai Beckley N.V.
Orchestra BioMed Holdings, Inc.
Similarity is computed from the 8 composite sub-scores and latest-quarter 13F conviction holdings (index-style filers excluded). Refreshed monthly.
More Healthcare Companies
View all Healthcare →Put INBX on your watchlist
Track score changes the day Inhibrx Biosciences, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is INBX a good stock to buy?
13F Pro's AI-powered analysis of Inhibrx Biosciences, Inc. (INBX) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for INBX are available on the INBX stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. INBX is classified as a small company.
Which hedge funds own INBX?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling INBX. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Inhibrx Biosciences, Inc.'s investment landscape.